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Abstract
Rationale Prepulse inhibition (PPI) of startle is a measure
of sensorimotor gating that is heritable and deficient in
certain psychiatric disorders, including schizophrenia.
Sprague–Dawley (SD) rats are more sensitive to PPI
disruptive effects of dopamine (DA) agonists at long
interstimulus intervals (60–120 ms) and less sensitive to
their PPI-enhancing effects at short (10–30 ms), compared
with Long–Evans (LE) rats. These heritable strain differences
insensitivity tothe PPI disruptive effects ofDAagonistsmust
ultimately reflect neural changes "downstream" from fore-
brain DA receptors.
Objective The current study evaluated the effects of the DA
agonist, apomorphine (APO), on ventral pallidal (VP)
gamma-aminobutyric acid (GABA) and glutamate efflux
and PPI in SD and LE rats.
Methods PPI was tested in SD and LE rats after vehicle or
APO (0.5 mg/kg, subcutaneously (s.c.)) in a within-subject
design. In different SD and LE rats, VP dialysate was
collected every 10 min for 120 min after vehicle or APO
(0.5 mg/kg, s.c.) and analyzed for GABA and glutamate
content by capillary electrophoresis (CE) coupled with
laser-induced fluorescence (LIF).
Results As predicted, SD rats exhibited greater APO-
induced PPI deficits at long intervals and less APO-
induced PPI enhancement at short intervals compared to
LE rats. APO significantly reduced VP GABA efflux in SD
but not in LE rats; glutamate efflux was unaffected in both
strains.
Conclusion Heritable strain differences in PPI APO sensi-
tivity in SD vs LE rats parallel, and may be mediated by,
strain differences in the VP GABA efflux.
Keywords Gamma-aminobutyricacid(GABA).
Microdialysis.Dopamine.Prepulseinhibition.
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Introduction
Prepulse inhibition (PPI) of the startle reflex is a cross-
species measure of sensorimotor gating, in which a
startle response is blunted by a weak lead stimulus
(Graham 1975;H o f f m a na n dI s o n1980). PPI is reduced in
individuals with specific brain disorders and in rats after
manipulations of limbic cortex, striatum, pallidum, or
pontine tegmentum (cf. Swerdlow et al. 2008). This limbic
cortico-striato-pallido-pontine circuitry has been studied
in rats to reveal the neurochemical and neuroanatomical
substrates regulating PPI at a high level of resolution. In
translational cross-species research, this detailed circuit
i n f o r m a t i o ni nr a t si su s e da sa“blueprint” to identify
substrates that may lead to PPI deficits in humans
(Swerdlow et al. 2001a).
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DOI 10.1007/s00213-009-1654-9PPI in rats is regulated by forebrain dopamine (DA)
receptors, with perhaps strongest evidence supporting a
primary role for the “D2-like” family of receptors in the
nucleus accumbens (NAC; Swerdlow et al. 1986;
Mansbach et al. 1988; Caine et al. 1995;W a na n d
Swerdlow 1997). One major mesolimbic “output” pathway
arising within NAC is a dense GABAergic projection into
the subpallidal regions that include the ventral pallidum
(VP; Jones and Mogenson 1980a, b). This striatopallidal
projection forms the next segment of a pervasive neural
circuit regulating central inhibitory mechanisms in mammals
(Mogenson 1987). Decreased PPI after NAC DA activation
might thus reflect reduced activity in GABAergic neurons
projecting from the NAC to the VP. Consistent with this
notion, the PPI disruptive effects of NAC DA infusion or
NAC cell lesions in rats are reversed by infusion of the
GABA agonist muscimol into the VP (Swerdlow et al. 1990;
Kodsi and Swerdlow 1994) or ibotenic acid lesions of the
VP (Kretschmer and Koch 1998) and are reproduced by
subpallidal infusion of the GABA antagonist, picrotoxin
(Swerdlow et al. 1990; Kodsi and Swerdlow 1995). We also
reported that systemic administration of the D3/D2 agonist,
quinelorane, disrupts PPI and decreases VP GABA release
(Qu et al. 2008). These studies suggest that NAC-mediated
decreases in PPI might result from reduced VP GABA
release.
Baseline and drug-induced changes in PPI exhibit robust
and heritable differences across rat strains. For example,
Sprague–Dawley (SD) rats are significantly more sensitive
than Long–Evans (LE) rats to the PPI disruptive effects of
both direct and indirect DA agonists (cf. Swerdlow et al.
2001a; Swerdlow et al. 2008), but not to the PPI disruptive
effects of serotonin agonists and N-methyl-D-aspartate
receptor antagonists (Swerdlow et al. 2003). This strain
difference in PPI sensitivity to DA agonists is heritable
(Swerdlow et al. 2004a, b), independent of fostering
conditions or differences in maternal–pup interactions
(Swerdlow et al. 2004a), stable across testing and breeding
facilities (Swerdlow et al. 2001b), and detectable as early as
postnatal day 18 (Swerdlow et al. 2004b). These strain
differences appear to be linked to differences in NAC DA-
stimulated signal transduction: They are accompanied by,
and correlate significantly with, strain differences in NAC
[
35S]GTPγS binding (Swerdlow et al. 2006), apomorphine
(APO)-induced changes in NAC phosphorylation of
cyclic adenosine monophosphate response element bind-
ing protein (Saint Marie et al. 2007), FOS expression
(Saint Marie et al. 2006), and gene expression (Shilling et
al. 2008). Differences in DA agonist sensitivity in SD vs
LE rats are also detected in behaviors other than PPI
(Swerdlow et al. 2006).
Strain differences in sensitivity to the PPI disruptive
effects of DA agonists must ultimately reflect changes
“downstream” from forebrain DA receptors, in efferent
projections that converge onto PPI-mediating circuitry in
the pons. By localizing the neural substrates responsible for
this heritable phenotype, we can develop models for
mechanisms by which genes modify brain circuitry to
generate phenotypes of relevance to brain disorders such as
schizophrenia. Evidence reviewed above indicates that the
PPI disruptive effects of DAergic activation of NAC
projection neurons are dependent on reduced GABAergic
activity in the VP. Thus, because strain differences in PPI
APO sensitivity appear to be mediated via differences in
DA-dependent signal transduction in the NAC, there is
strong inference that they should be accompanied by
differences in the effects of DA agonists on VP GABA
release. In fact, any other outcome would force a
re-evaluation of evolving models for the neural regulation
of PPI. In this study, we compared APO effects on VP
GABA release in SD vs LE rats. To assess the neurochemical
specificityofanyfinding,the effects ofAPO onVPglutamate
dialysate were also compared across strains.
Materials and methods
Animals Male SD and LE rats (n=30/strain; 225–300 g;
Harlan laboratories) were housed in a temperature-
controlled vivarium (22°C), maintained on a 12-h reversed
light/dark cycle (lights off 7:30AM, lights on 7:30PM), and
given ad. libitum access to food and water. All testing
occurred between 8AM to 4PM. Rats were handled within
48 h of arrival and allowed to acclimate to the laboratory
for 7 days prior to behavioral testing or surgery. Studies
were conducted in accordance with the “Guide for Care and
Use of Laboratory Animals” provided by the National
Institutes of Health.
Drugs and reagents Apomorphine (0.5 mg/kg) or vehicle
(0.1% ascorbate in saline) was administered subcutaneously
(s.c.) to rats.
In vivo microdialysis Rats (n=15/strain) received 1 ml/kg
(sc) atropine sulfate solution (0.054 mg/ml, Vedco. Inc., St.
Joseph, MO 64507, USA) before being anesthetized with
1.4 ml/kg (intraperitoneally (i.p.)) Nembutal sodium solu-
tion (50 mg/ml, Ovation Pharmaceuticals Inc., Deerfield, IL
60015, USA) and placed in a Kopf stereotaxic instrument
(tooth bar at −3.3 mm). Intracerebral microdialysis guide
cannulae (1.0 mm OD; MAB 2.20.G, SciPro Inc, Sanborn,
NY, USA) were stereotaxically implanted to terminate
1 mm above the VP (when inserted, the dialysis probe
extended ~2 mm from the cannula tip, and the distal 1 mm
contained the dialysis membrane (0.6 mm OD; MAB
6.20.1, SciPro Inc)). Probes were unilateral, with sides
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were predetermined based on the distribution of substance
P immunoreactivity in the VP for each strain (see Fig. 1).
Dialysis began 7–10 days after surgery.
Dialysis experiments were conducted between 8AM and
3AM in a sound-controlled environment. Rats remained in
their home cage with bedding, food, and water bottle
throughout the experiment. Each rat was lightly anesthe-
tized (0.5 ml/kg sodium pentobarbital solution (50 mg/ml,
i.p.) Ovation Pharmaceuticals Inc., Deerfield, IL 60015,
USA). The microdialysis probe was inserted and secured to
the guide cannula in the afternoon before sample collection
and perfused with artificial cerebrospinal fluid (pH 7.2–7.4;
149 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM
MgCl2, 5.4 mM d-glucose, 0.25 mM ascorbate) delivered
via a liquid swivel at 0.2 μl/min overnight. The
next morning, the perfusion flow rate was increased to
0.6 μl/min, and background noise was maintained at 60 dB
(A). After 1-h equilibration and habituation, dialysate
samples were collected in polypropylene tubes at 10-min
intervals over a 60-min baseline period. Rats then received
either 0.5 mg/kg APO or vehicle (s.c.), and dialysate
sampling continued at 10-min intervals for an additional
2 h. This active dose of APO yields the maximal difference
in PPI APO sensitivity in SD vs LE rats, based on several
published reports from our group of full dose-response
characteristics (e.g., Swerdlow et al. 2001b, 2002, 2004b, c).
After collection, the samples were frozen on dry ice and
stored at −70°C.
Probe placement verification and substance P immunohisto-
chemistry After the dialysis session, rats were given an
overdose of pentobarbital and perfused transcardially with
saline, followed by fixation with 10% buffered formalin
(pH 7.0). Brains were dissected and cryoprotected for
3 days in the buffered formalin plus 30% sucrose. Frozen
brain sections (40 μm) were cut in the coronal plane with a
sliding microtome, and mounted sections were then Nissl
stained to confirm probe placement (e.g., Figs. 1 and 2).
Placement was determined by comparing stained sections to
a standard rat brain stereotaxic atlas (Paxinos and Watson
1998). Only two rats had placements that fell outside of the
VP, and their results were excluded from the final analysis.
Additional rats (n=3/strain) had cannulae and probes
implanted to verify placement based on substance P
immunoreactivity of the ventral pallidum. These rats were
perfused immediately after surgery, with the probe in place,
and the fixation solution was 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4). In these cases, frozen
brain sections (40 μm) were collected in commercial Tris-
buffered saline (TBS, pH 7.4), and all subsequent solutions
were made with this TBS. Endogenous peroxidase activity
was suppressed by pre-exposure of the sections to 0.525%
H2O2 for 20 min, and this was followed by 2 h in a
blocking solution containing 10% normal horse serum
(Invitrogen, Carlsbad, CA, USA) and 0.33% Triton
X-100. Sections were then incubated overnight with a
substance P antiserum (Invitrogen, Carlsbad, CA, USA),
diluted 1:1000 with the blocking solution. After intervening
Fig. 1 Probe placement in a Nissl-stained section of a dialyzed rat (left)
and in a substance P immunostained section (right). Dark substance P
staining clearly outlines the VP (right). From the base of the guide
cannula tracts (double headed arrows), the dialysis probes extend
~2 mm, with the ventralmost 1 mm containing the dialysis membrane
(0.6 mm OD). Substance P staining and the presence of the decussating
anterior commissure (ac) were used initially to determine the appropri-
ate AP coordinates for probe placement in SD (−0.30) and LE (+0.20)
rats. Other coordinates (from Bregma) were the same for both strains:
ML±2.5 mm; DV –6.3 mm (after Paxinos and Watson 1998)
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lated donkey antirabbit serum (Jackson ImmunoResearch,
West Grove, PA, USA) for 4 h, diluted 1:800 with the
blocking solution; (2) avidin-biotin-peroxidase reagent
(Standard Elite ABC Kit, Vector Laboratories, Burlingame,
CA, USA) overnight, diluted 1:100 with TBS plus 0.33%
Triton X; and (3) reacted with a diaminobenzidine/NiCl
peroxidase substrate kit solution (Vector Laboratories). An
example is presented in Fig. 1b.
Digital images were acquired with a Leitz Laborlux S
microscope equipped with a Polaroid DMC-1 digital
camera and software. Digital micrographs presented in this
report (Fig. 1a and b) were processed to correct for
background illumination and contrast only.
Sample analysis Microdialysate GABA and glutamate
content were determined using CE-LIF detection as
previously described (Caille and Parsons 2004, 2006;
O’Dell et al. 2006;O ’Dell and Parsons 2004; Roberto et
al. 2004a, b). GABA and glutamate were derivatized by
mixing 4–6 μl of microdialysate with 9 μl of 40 mM borate
buffer (pH 10.5) containing 3.8 mM KCN and 1.5 μlo f
5 mM naphthalene-2,3-dicarboxaldehyde in methanol. This
mixture was reacted at room temperature in the dark for
60 min before loading into the CE instrument (Agilent
Technologies, Wilmington, DE, USA) by 50 millibars of
pressure for 10 s. GABA and glutamate were separated on a
90-cm fused silica capillary (30 μm inner diameter) by
using 15 kV and a background electrolyte solution consist-
ing of 200 mM borate buffer, pH 9.2, containing 34 mM
SDS and 2.5 mM 2-hydroxypropyl)-β-cyclodextrin. GABA
and glutamate were detected using a LIF detector (Zetalif,
Picometrics) that employs a 442 nm HeCd laser (30 mW,
Melles Griot). External calibration standards were run in
duplicate throughout the sample run. The limits of
quantification are approximately 1 nM for each of the
analytes, which is well below the concentration of GABA
and glutamate typically found in these microdialysis
samples (Caille and Parsons 2004, 2006;O ’Dell et al.
2006;O ’Dell and Parsons 2004; Roberto et al. 2004a, b).
PPI testing Separate experimental groups (n=12/strain)
were used for behavioral and neurochemical measures. All
startle experiments utilized four startle chambers (SR-LAB;
San Diego Instruments, San Diego, CA, USA) housed in a
sound-attenuated room with a 60-dB ambient noise level.
Each startle chamber consisted of a Plexiglas cylinder,
8.7 cm in internal diameter, resting on a 12.5 × 25.5-cm
Plexiglas stand. Acoustic stimuli and background noise
were presented via a Radioshack Supertweeter mounted
24 cm above the Plexiglas cylinder. Startle magnitude was
detected and recorded as transduced cylinder movement via
a piezoelectric device mounted below the Plexiglas stand.
Acoustic stimulus intensities and response sensitivities were
calibrated to be nearly identical in each of the four startle
chambers (maximum variability <1% of stimulus range and
<5% of response ranges) by using an SR-LAB Startle
Calibration System. Chambers were also balanced across
all experimental groups. Sound levels were measured and
calibrated with a sound level meter (Quest electronics:
Oconomowoc, WI, USA), A scale (relative to 20 N/M2),
with microphone placed inside the Plexiglas cylinder.
Rats were exposed to a brief ‘matching’ startle session
used to assign rats to balanced drug groups according to
their average level of PPI. Four days later, rats were treated
with APO (0.5 mg/kg) or vehicle (0.1% ascorbate in saline)
and placed immediately into the startle chambers. As noted
above, this active dose was determined in several previous
full dose-response studies to yield the maximal difference
in SD vs LE PPI APO sensitivity. Each session was
approximately 65 min long, began with a 5-min acclimation
to a 70 dB(A) background noise followed by six
10-min trial blocks containing 6 trial types: PULSE
(120 dB(A) 40-ms noise bursts); PULSE preceded 10, 30,
or 120 ms by a 5-ms noise burst, 12 dB above background;
PREPULSE (5-ms noise bursts 12 dB above 70-dB
background); and a NOSTIM trial (no stimulus delivery).
Each block began with a PULSE trial and in total consisted
of five PULSE trials, 15 PREPULSE + PULSE trials (five
of each PREPULSE type), 3 PREPULSE trials, and 24
NOSTIM trials. Trials other than NOSTIMs were presented
in pseudorandom order with a variable intertrial interval
SD LE
SD LE
VP
VP
ac
ac ac
VP
VP
Fig. 2 Schematic representation of probe placements for all dialysis
cases. Regardless of the side dialyzed, which was balanced for each
strain, Sprague–Dawley (SD) rats are represented on the left, Long–
Evans (LE) on the right. Illustrations are adapted from Paxinos and
Watson (1998). VP ventral pallidum, ac anterior commissure
274 Psychopharmacology (2009) 207:271–280(average of 15 s). NOSTIM trials were interspersed
between each consecutive stimulus trials and were used to
assess gross motor activity during the test session, but were
not included in the calculation of intertrial intervals. Each
block ended with a stimulus-free period, lasting 4 min 15 s.
Data collection and analysis Between-group differences in
baseline microdialysate GABA concentrations were first
compared by analysis of variance (ANOVA). After confir-
mation that strains did not differ in baseline VP GABA
efflux, post-injection data for each rat were converted to a
value corresponding to a percent of the average baseline
concentration obtained for 60 min prior to the injection.
The effects of drug on VP dialysate levels of GABA and
glutamate were then evaluated using ANOVAwith repeated
measures over time, with dose and strain as between-
subjects factor.
Startle magnitudes were calculated for each trial in the
20–100-ms time window following startle stimulus onset.
Startle magnitude was examined separately for the
PULSE trials that were interspersed among the PRE-
PULSE + PULSE trials, vs those that were presented at
the onset of each trial block. PPI was calculated as a
percent reduction in startle magnitude on PREPULSE +
PULSE trials compared to PULSE trials, i.e., 100   startle ð ½
amplitude on PREPULSE þ PULSE trials=startle amplitude
on PULSE trialsÞ 100 . Any drug effects on %PPI promp-
ted separate analyses to assess the relationship of these
effects to drug-induced changes in startle magnitude on
PULSE trials. All startle magnitude data were analyzed using
ANOVAs with dose and strain as the between-subject factor,
respectively. Post hoc comparisons of significant interaction
effects and relevant main factor effects were conducted using
Fisher’s protected least significant difference and one-factor
ANOVA tests.
Results
GABA efflux A summary of probe placements used in the
following analyses are presented in Fig. 2. Baseline GABA
concentrations of SD and LE rats in VP dialysates were
stable over 60 min, did not differ between strains, and did
not differ between rats subsequently randomized to vehicle
vs APO treatment groups in each strain (SD, vehicle vs
APO: 57.14±13.04 nM vs 58.22±11.76 nM; LE, vehicle vs
APO: 51.67±8.95 nM vs 52.38±8.31 nM). ANOVA of
baseline GABA revealed no significant effect of strain,
group assignment, strain x group assignment interaction,
time block, time block x strain interaction, time block x
group assignment interaction, or time block x strain x group
assignment interaction. Dialysate data were then expressed
as a percent of baseline level, based on the mean levels
across the 60-min pre-drug sampling period (Fig. 3a, b).
ANOVA of post-injection GABA efflux revealed no
significant effect of strain or APO dose, but a significant
dose x strain interaction (F=5.90, df 1, 26, p<0.022). There
was a significant effect of time (F=2.07, df 11, 286, p<
0.023), but no significant interactions of time x dose, time x
strain, or time x dose x strain. GABA efflux in SD rats after
0.5 mg/kg APO treatment declined rapidly to almost 60%
baseline levels (F=10.92, df 1, 11, p=0.007), where it
remained for 120 min. By contrast, APO treatment did not
significantly change GABA efflux in LE rats. There was no
significant interaction of dose x time for SD or LE rats.
Glutamate efflux Baseline VP glutamate concentrations of
SD and LE rats dropped during the initial 10 min of
sampling but were stable over the subsequent 50 min
of baseline collection (effect of time block, minutes 0–60:
F=4.20, df 5, 120, p<0.002; minutes 10–60: NS), did not
differ between strains, and did not differ between rats
subsequently randomized to vehicle vs APO treatment
groups in each strain (SD, vehicle vs APO: 1.33±0.28 μM
vs 1.41±0.22 μM; LE, vehicle vs APO: 1.97±0.45 μMv s
1.89±0.51 μM). ANOVA revealed no significant effect of
strain, group assignment, or strain x group assignment
interaction. Glutamate efflux was then calculated as a
percent of baseline values, based on the mean levels across
the 60-min predrug sampling period (Fig. 3c, d). ANOVA
of %baseline efflux revealed no significant effect of strain,
APO dose, or strain x dose interaction. There was a
significant effect of time block (F=1.96, df 11, 264, p<
0.04) reflecting a postinjection spike in two LE rats injected
with vehicle, but no significant interactions of time block x
strain, time block x dose, or time block x strain x dose.
Behavior PPI in SD and LE rats is seen in Fig. 4, for the
same postdrug time period assessed in the above micro-
dialysis studies. ANOVA of PPI revealed a significant
effect of strain (F=10.08, df 1, 22, p<0.005), no main
effect of APO dose (F=3.17, df 1, 22, p<0.09), a
significant effect of prepulse interval (F=83.12, df 2, 44,
p<0.0001), and significant interactions of dose x strain (F=
7.54, df 1, 22, p<0.015), dose x interval (F=26.67, df 2, 44,
p<0.0001), and dose x strain x interval (F=4.33, df 2, 44,
p<0.02). There was no significant effect of time block, but
significant interactions of time x dose (F=2.75, df 5, 110,
p<0.025), time x interval (F=3.07, df 10, 220, p<0.002),
and time x dose x strain x interval (F=2.34, df 10, 220, p<
0.015). Post hoc comparisons confirmed patterns identical
to those reported previously: compared to LE rats, SD rats
exhibited a greater APO-induced reduction in PPI at long
prepulse intervals and a weaker APO-induced increase in PPI
at short prepulse intervals (specific statistical comparisons are
Psychopharmacology (2009) 207:271–280 275identified in Fig. 4). APO effects on PPI in both strains were
prominent for 30–40 min and then, waned by 60-min post-
injection.
Analysis of startle magnitude on PULSE trails during
PPI testing (as shown in Fig. 5a) revealed significant main
effects of strain (LE > SD; F=5.25, df 1, 22, p<0.032) and
time block (F=16.99, df 5, 110, p<0.0001) and a
significant interaction of strain x time block (F=2.56, df
5, 110, p<0.026; Fig. 5). However, there was no significant
main effect of APO dose, or significant interactions of dose
x strain, or dose x strain x time block (F=1.09, df 5, 110,
NS). Therefore APO effects on startle magnitude were
clearly dissociated from those on PPI in SD and LE rats.
Similarly, startle habituation (measured from the initial to
final startle trials in the session, as shown in Fig. 5b) was
not significantly impacted by APO dose or by an
interaction of dose x strain.
Analysis of cage displacement after prepulses presented
alone, and gross motor activity (NOSTIM levels) during
this 60-min period (Table 1) revealed significant effects of
strain on both measures (p<0.04 and p<0.05, respectively)
and a significant effect of APO dose on gross motor activity
(p<0.01). Most critically, the interaction of strain x APO
dose was not significant for either of these measures.
Discussion
The major finding in the present study is that systemic
administration of APO causes a sustained reduction of VP
GABA efflux in SD, but not LE rats. Strain differences in
APO effects on PPI reproduced previous findings (e.g.,
Swerdlow et al. 2004a; Shilling et al. 2008) that compared
with LE rats, SD rats are more sensitive to the PPI
disruptive effects of APO at long prepulse intervals and
less sensitive to the PPI-enhancing effects of APO at short
prepulse intervals.
The most important implication of this finding is that it
appears to localize the neural circuit basis for this strain
difference in PPI APO sensitivity at, or “upstream” from,
the NAC medium spiny neuron (MSN) efferent projection.
Thus, a neural event known to reduce PPI—reduced VP
GABAergic transmission—is triggered by APO in SD but
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Fig. 3 VP GABA efflux (% Baseline) in SD (a) and LE (b) rats after
vehicle or 0.5 mg/kg APO s.c. (at Time=0 min). GABA efflux after
APO in SD rats declined rapidly to almost 60% baseline levels, where
it stayed for 120 min. * Significant reduction in VP GABA efflux
compared to vehicle dose (all p values<0.05). GABA efflux after
APO in LE rats remained relatively stable. VP glutamate efflux (%
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s.c. (at Time=0 min). No significant effects of drug or strain on VP
glutamate efflux were detected, though an injection artifact was noted
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276 Psychopharmacology (2009) 207:271–280not LE rats. While this finding does not preclude other
strain differences in “downstream” circuitry in the VP or
pons, there appears to be a strain-based difference in NAC
MSN efferent activity that could account for the heritable
behavioral phenotype. This finding supports the possibility
that reported strain differences in intracellular mechanisms
in NAC MSNs—such as DA-linked signaling (Swerdlow et
al. 2005; Saint Marie et al. 2006, 2007) or gene expression
(Shilling et al. 2008)—might be “upstream” events respon-
sible for the phenotypic differences in APO effects on both
VP GABA efflux and PPI. To the degree that the present
model reflects a heritable “vulnerability” to a pathological
DA-mediated deterioration in sensorimotor gating, these
findings suggest that therapeutic targets for such pathology
lie upstream from the VP GABA synapse, within the MSN
signaling pathways.
The aim of this study was relatively narrow: to test the
falsifiable hypothesis that SD vs LE differences in PPI APO
sensitivity should be accompanied by differences in VP
GABA efflux. A single dose of APO was selected, based
on evidence from numerous past dose-response studies that
it would yield maximal strain differences in PPI sensitivity
(e.g., Swerdlow et al. 2001b, 2002, 2004b, c). Had this
dose yielded the expected strain difference in PPI APO
sensitivity, absent the predicted difference in VP GABA
efflux, the hypothesis would have been falsified. This was
not the case. Certainly, a full dose-response characterization
of the effects of APO on VP GABA efflux would provide
additional layers of information; based on the differential
sensitivity and dynamic ranges of very distinct measures
(startle and CE-LIF), it would not be surprising if these
measures were to diverge at either end of the dose-response
range. The goal of this study, however, was not to provide a
comprehensive physiological profile of this brain-behavior
relationship: rather, it was to select a dose that yields a
maximal behavioral signal and to test the clear prediction that
it should be accompanied by a specific neurochemical signal.
The VP is also innervated by glutamatergic projections,
arising from the frontal cortex, amygdaloid, and subthala-
mic nuclei (Delgado-Martinez and Vives 1993; Fuller et al.
1987; Groenewegen and Berendse 1990; Kretschmer et al.
2000). The present findings suggest that strain differences
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for 10, 30, and 120 ms prepulse
intervals, across the 60-min test
session. As predicted, APO
markedly disrupted long interval
PPI in SD (but not LE rats), and
APO enhanced short interval
PPI in LE (but not SD) rats.
Both effects waned prior to the
change in SD VP GABA efflux,
as seen in Fig. 3. * Significant
PPI-reducing effect of APO (all
p values<0.05); # significant
PPI-enhancing effects of APO
(all p values<0.05)
Psychopharmacology (2009) 207:271–280 277in PPI APO sensitivity are not associated with differences
in the effect of APO on these VP glutamate projections as a
group, but do not preclude the possibility that one or more
of these projections might differ across strains, in a manner
that is either diluted or otherwise masked by other
converging glutamate inputs.
Conversely, striatal GABAergic projections innervate the
full extent of the globus pallidus (GP), among many other
structures. Others have reported changes in GP GABAergic
efflux in response to systemic administration of DA
agonists and antagonists (e.g., Robertson et al. 1991;
Opacka-Juffry et al. 1998), and it is fully expected that
the systemic administration of APO in this study resulted in
changes in GABAergic and other forms of neurotransmis-
sion throughout the rat brain. Some of these changes might
also contribute to the PPI disruptive effects of APO; indeed,
our group first reported on the importance of dorsal
striatopallidal GABAergic projections in the regulation of
PPI (Kodsi and Swerdlow 1995). As noted above, our
narrow focus on VP GABA efflux in the present study was
designed to test a specific hypothesis based on reports that
identify the NAC-VP projection as a potent mediator of the
PPI disruptive effects of DA agonists and as a candidate
neural substrate for heritable differences in the sensitivity to
these effects. The outcome of this study could have falsified
this hypothesis, but it did not.
Across the 60-min time course of this PPI session, there
was a clear temporal dissociation (implying a functional
dissociation) of APO effects on PPI from those on startle
magnitude, prepulse-elicited motor activity, and baseline
“NOSTIM” activity. Furthermore, APO effects on PPI in
both strains are fully resolved after 60 min of testing, while
those on VP GABA efflux in SD rats persist for at least
120 min. We reported a similar pattern of persistent changes
in VP GABA efflux despite a resolution of PPI changes, in
response to quinelorane (Qu et al. 2008). Conceivably, the
waning of the APO effect on PPI may reflect changes
“downstream” from GABA release, e.g., via an upregula-
tion of VP GABA receptors or comparable forms of
neuroadaptation. It is also possible that APO effects on
VP GABA efflux (like those on PPI) might be curtailed
after 60 min of repeated startle-evoking stimuli; this
hypothesis could be tested via the delivery of startling
stimuli to rats during VP GABA dialysis.
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Fig. 5 Startle magnitude during PPI testing (a) and on the first trial of
each block (b) in SD and LE rats
Table 1 APO effects on startle habituation, cage displacement after prepulses alone, and gross motor activity (NOSTIM levels)
Main effect/interaction Startle habituation Cage displacement after prepulses
presented alone
a
Gross motor activity
b
(NOSTIM levels)
F value df P F value df P F value df P
Strain 7.27 1, 22 0.013 4.91 1, 22 0.037 4.97 1, 22 0.04
APO <1 <1 8.41 1, 22 0.008
Strain x APO <1 <1 3.38 1, 22 NS
Time blocks 25.8 5, 110 <0.0001 1.17 5, 110 NS 3.38 5, 110 0.007
Time blocks x strain 3.07 5, 110 0.012 2.81 5, 110 0.02 2.35 5, 110 <0.05
APO x time blocks <1 <1 4.98 5, 110 0.0004
APO x time blocks x strain <1 <1 2.48 5, 110 0.04
APO apomorphine
aMean (SEM) cage displacement after prepulse presented alone: Sprague–Dawley rats=0.76 (2.5), Long–Evans rats=0.18 (1.2)
bPost hoc comparisons: APO increased NOSTIM activity in SD rats in block 1 (p<0.03), block 2 (p<0.03), block 3 (p<0.02), block 4 (p<0.04),
and decreased NOSTIM activity in LE rats in block 3 (p<0.05), but increased NOSTIM activity in block 5 (p<0.05)
278 Psychopharmacology (2009) 207:271–280In summary, strain differences in the PPI disruptive
effects of APO are accompanied by predicted, parallel
changes in VP GABA efflux. Heritable and presumably
genetic mechanisms mediating an enhanced “vulnerability”
to the gating-disruptive effects of DA activity appear to be
acting upstream from the VP GABA synapse, most likely
within intracellular signaling pathways in medium spiny
GABAergic efferents from the NAC. Molecules in these
pathways are being explored as potential targets of strong
inference for therapeutic interventions in disorders of
heritable gating deficits.
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